Jeffrey A. Meyerhardt

52.7k citations

431 papers · 25.8k indexed · 10 hit papers · h-index 85

Impact in

Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Surgical Treatments
Pathology and Forensic Medicine top 0.05%
- Genetic factors in colorectal cancer

Papers in

Oncology 290
- Colorectal Cancer Treatments and Studies 113
- Colorectal Cancer Screening and Detection 65
- Cancer survivorship and care 53
Pathology and Forensic Medicine 100
- Genetic factors in colorectal cancer 75

Co-authors: Charles S. Fuchs Robert J. Mayer Edward L. Giovannucci Shuji Ogino Andrew T. Chan Katsuhiko Nosho Kimmie Ng Kaori Shima
Journals: Journal of Clinical Oncology (120 papers)Cancer (17 papers)Clinical Cancer Research (16 papers)Cancer Epidemiology Biomarkers & Prevention (16 papers)JNCI Journal of the National Cancer Institute (15 papers)
Partner nations: United States Canada China

In The Last Decade

Jeffrey A. Meyerhardt

416 papers receiving 25.4k citations

Hit Papers

10 papers align trajectories log scale

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas 2022 · 144 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 JAMA Oncology
2022 Journal of Clinical Oncology
2021 Journal of Clinical Oncology
2017 JAMA Oncology
2017 Journal of Clinical Oncology
2012 New England Journal of Medicine
2012 CA A Cancer Journal for Clinicians
2006 Journal of Clinical Oncology
2006 Journal of Clinical Oncology
2005 New England Journal of Medicine

Peers

Countries citing papers authored by Jeffrey A. Meyerhardt

Since Specialization

Citations

This map shows the geographic impact of Jeffrey A. Meyerhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Meyerhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Meyerhardt more than expected).

Fields of papers citing papers by Jeffrey A. Meyerhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Meyerhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Meyerhardt. The network helps show where Jeffrey A. Meyerhardt may publish in the future.

Co-authors

The 25 scholars most cited alongside Jeffrey A. Meyerhardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeffrey A. Meyerhardt Line = papers co-authored together Jeffrey A. Meyerhardt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial Cancer Prevention Research ·Justin C. Brown, Sui Zhang, Jennifer A. Ligibel, Melinda L. Irwin, Lee W. Jones, Nancy Campbell, Michaël Pollak, Angga Saputra Kanisius, Brenda Cartmel, Maura Harrigan, Sara M. Tolaney, Eric P. Winer, Kimmie Ng, Thomas A. Abrams, Tara Sanft, Pamela S. Douglas, Frank B. Hu, Charles S. Fuchs, Jeffrey A. Meyerhardt	2020	31
2	Physical Activity and Risk of Hepatocellular Carcinoma Among U.S. Men and Women Cancer Prevention Research ·Perea Camargo, Wanshui Yang, Yanan Ma, Tracey G. Simon, Jeffrey A. Meyerhardt, Andrew T. Chan, Edward L. Giovannucci, Xuehong Zhang	2020	8
3	A Prospective Study of Nut Consumption and Risk of Primary Hepatocellular Carcinoma in the U.S. Women and Men Cancer Prevention Research ·Jing Sui, Wanshui Yang, Yanan Ma, Tricia Y. Li, Tracey G. Simon, Jeffrey A. Meyerhardt, Geyu Liang, Edward L. Giovannucci, Andrew T. Chan, Xuehong Zhang	2019	20
4	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance) Clinical Cancer Research ·Chen Yuan, Kaori Sato, Bruce W. Hollis, Sui Zhang, Donna Niedzwiecki, Fang‐Shu Ou, Zhenzhong Rao, Bert H. O’Neil, Federico Innocenti, Heinz‐Josef Lenz, Charles D. Blanke, Richard M. Goldberg, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kimmie Ng	2019	44
5	Calcium Intake and Survival after Colorectal Cancer Diagnosis Clinical Cancer Research ·Wanshui Yang, Yanan Ma, Michel Rosier, Mingyang Song, Kana Wu, Molin Wang, Andrew T. Chan, Shuji Ogino, Charles S. Fuchs, Vitaliy Poylin, Kimmie Ng, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Xuehong Zhang	2018	32
6	Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study) Cancer Epidemiology Biomarkers & Prevention ·Bette J. Caan, Jeffrey A. Meyerhardt, Candyce H. Kroenke, Stacey Alexeeff, Jingjie Xiao, Erin Weltzien, Elizabeth M. Cespedes Feliciano, Adrienne Castillo, Charles P. Quesenberry, Marilyn L. Kwan, Carla M. Prado	2017	261
7	MicroRNA let-7 , T Cells, and Patient Survival in Colorectal Cancer Cancer Immunology Research ·Ruoxu Dou, Reiko Nishihara, Yin Cao, Tsuyoshi Hamada, Kosuke Mima, Atsuhiro Masuda, Yohei Masugi, Yan Shi, Mancang Gu, Wanwan Li, Annacarolina da Silva, Katsuhiko Nosho, Xuehong Zhang, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Andrew T. Chan, Charles S. Fuchs, Zhi Rong Qian, Shuji Ogino	2016	43
8	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer Clinical Cancer Research ·Nadine J. McCleary, Kaori Sato, Reiko Nishihara, Kentaro Inamura, Teppei Morikawa, Xuehong Zhang, Kana Wu, Mai Yamauchi, Sun A. Kim, Yasutaka Sukawa, Kosuke Mima, Zhi Rong Qian, Charles S. Fuchs, Shuji Ogino, Jeffrey A. Meyerhardt	2015	11
9	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma The Oncologist ·Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary, Peter C. Enzinger, Charles S. Fuchs, Nadine J. McCleary, Jeffrey A. Meyerhardt, Kimmie Ng, Deborah Schrag, David Eduardo, Beverly Spicer, Noelia Morillo Gallego, Harvey J. Mamon, Alec C. Kimmelman	2014	289
10	Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer The Oncologist ·Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas A. Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, Tomas Goldberger, Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, Charles S. Fuchs	2013	38
11	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database Journal of Clinical Oncology ·Nadine J. McCleary, Jeffrey A. Meyerhardt, Erin Green, Greg Yothers, Aimery de Gramont, Eric Van Cutsem, Michael J. O’Connell, Christopher Twelves, Leonard B. Saltz, Daniel G. Haller, Daniel J. Sargent	2013	157
12	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study Clinical Cancer Research ·Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine J. McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Hayer Georg, ano, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, Dan G. Duda	2013	55
13	Physical Activity, Tumor PTGS2 Expression, and Survival in Patients with Colorectal Cancer Cancer Epidemiology Biomarkers & Prevention ·Mai Yamauchi, Paul Lochhead, Yu Imamura, Aya Kuchiba, Xiaoyun Liao, Zhi Rong Qian, Reiko Nishihara, Teppei Morikawa, Kaori Shima, Kana Wu, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs, Andrew T. Chan, Shuji Ogino	2013	33
14	Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors Journal of Clinical Oncology ·Jennifer A. Chan, Keith Stuart, Craig C. Earle, Jeffrey W. Clark, Pankaj Bhargava, Rebecca A. Miksad, Lawrence S. Blaszkowsky, Peter C. Enzinger, Jeffrey A. Meyerhardt, Hui Zheng, Charles S. Fuchs, Matthew H. Kulke	2012	207
15	Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers Clinical Cancer Research ·Yu Imamura, Teppei Morikawa, Xiaoyun Liao, Paul Lochhead, Aya Kuchiba, Mai Yamauchi, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Kevin M. Haigis, Charles S. Fuchs, Shuji Ogino	2012	210
16	Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review Clinical Cancer Research ·Xiaoyun Liao, Teppei Morikawa, Paul Lochhead, Yu Imamura, Aya Kuchiba, Mai Yamauchi, Katsuhiko Nosho, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Charles S. Fuchs, Shuji Ogino	2012	200
17	Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 Clinical Cancer Research ·Shuji Ogino, Kaori Shima, Jeffrey A. Meyerhardt, Nadine J. McCleary, Kimmie Ng, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B. Benson, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagnolli, Charles S. Fuchs	2011	207
18	Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype Clinical Cancer Research ·Shuji Ogino, Katsuhiko Nosho, Natsumi Irahara, Jeffrey A. Meyerhardt, Yoshifumi Baba, Kaori Shima, Jonathan N. Glickman, Cristina R. Ferrone, Mari Mino–Kenudson, Noriko Tanaka, Glenn Dranoff, Edward L. Giovannucci, Charles S. Fuchs	2009	308
19	A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases Clinical Cancer Research ·Shuji Ogino, Katsuhiko Nosho, Natsumi Irahara, Shoko Kure, Kaori Shima, Yoshifumi Baba, Saori Toyoda, Li Chen, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs	2009	65
20	Getting Knit-PI3Ky: PIK3CA Mutation Status to Direct Multimodality Therapy? Clinical Cancer Research ·Andrea P. Myers, Jeffrey A. Meyerhardt, Lewis C. Cantley	2009	1

About Jeffrey A. Meyerhardt

Jeffrey A. Meyerhardt is a scholar working on Oncology, Pathology and Forensic Medicine, Geriatrics and Gerontology, Cancer Research and Physiology, having authored 431 papers that have together received 25.8k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (113 papers), Genetic factors in colorectal cancer (75 papers), Nutrition and Health in Aging (74 papers), Colorectal Cancer Screening and Detection (65 papers), Cancer survivorship and care (53 papers), Nutritional Studies and Diet (50 papers), Cancer, Lipids, and Metabolism (47 papers) and Gastric Cancer Management and Outcomes (45 papers). The work is most often cited by research in Oncology (16.3k citations), Pathology and Forensic Medicine (5.4k citations), Cancer Research (3.9k citations), Geriatrics and Gerontology (941 citations) and Physiology (5.0k citations). Jeffrey A. Meyerhardt has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Charles S. Fuchs, Robert J. Mayer, Edward L. Giovannucci, Shuji Ogino, Andrew T. Chan, Katsuhiko Nosho, Kimmie Ng, Kaori Shima, Kana Wu and Brian M. Wolpin. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Cancer Epidemiology Biomarkers & Prevention and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact